目的 研究孟魯司特鈉聯(lián)合沙美特羅氟替卡松治療支氣管哮喘患者的效果。方法 采用前瞻性研究方法，選擇2014年4月-2016年3月在四川省第四人民醫(yī)院診治的98例支氣管哮喘患者作為研究對(duì)象，根據(jù)隨機(jī)抽簽原則把上述患者分為觀察組與對(duì)照組各49例，對(duì)照組給予沙美特羅氟替卡松治療，觀察組給予孟魯司特鈉聯(lián)合沙美特羅氟替卡松治療，均治療觀察15d，比較兩組臨床療效、肺功能及生活質(zhì)量評(píng)分情況。結(jié)果 治療后觀察組總有效率為95.9%，明顯高于對(duì)照組的81.6%，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后兩組FEV1、FVC值和ACT評(píng)分都明顯高于治療前，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05），且治療后觀察組以上指標(biāo)明顯高于對(duì)照組，組間比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療期間，兩組不良反應(yīng)率無(wú)統(tǒng)計(jì)學(xué)差異。結(jié)論 孟魯司特鈉聯(lián)合沙美特羅氟替卡松治療支氣管哮喘患者能促進(jìn)肺功能的改善，從而提高治療療效與生活質(zhì)量。

Objective To compare the effects of salmeterol and fluticasone propionate combined montelukastin the treatment of patients with bronchial asthma. Methods Ninety-eight bronchial asthma patients from April 2014 to March 2016in the Fourth People’s Hospital Sichuan Province were selected anddivided into observation group and control group with 49 patients in each group according to the above principles by prospective study. The control group was given salmeterol treatment, and the observation group was added given montelukast treatment based on the control group.The treatment days were 15d recorded the prognosis of the two groups. Results The total effective rates of the observation group and the control group were 95.9% and 81.6% respectively, the total effective rate of the observation group was significantly higher than that of the control group (P<0.05). The FEV1 and FVC values after treatment in the observation group and control group were significantly higher than before treatment (P<0.05), while the FEV1 and FVC values in the observation group after treatment were significantly higher than those in the control group (P<0.05). The scores of ACT scale after treatment of two groups were obviously higher than before treatment, and the score of observation group was statistically higher than control group after treatment (P<0.05).During treatment, there was no statistical significance on adverse reaction between two groups.Conclusion Salmeterol and fluticasone propionate combined montelukast in the treatment of patients with bronchial asthma can promote the improvement of lung function, so as to improve the quality of life and clinical treatment.